Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 0.02% Betamethasone Sodium Phosphate
0.02% Betamethasone · 1 trial · 1 indication
The UNC DEMS scale is a participant-specific 10-point scale with a minimum score of 1 (\[1-2\] My symptoms are not a problem. My dry eye does not affect my daily life at all) and a maximum score of 10 (\[9-10\] my symptoms are severe and I need immediate medical care. My dry eye greatly affects my daily life). Participants with a minimum reduction of ≥1 point in UNC DEMS score from baseline were defined as responders, and response rates were summarized by treatment group.
| Arm | Type | Description |
|---|---|---|
| SURF-200 (0.02% betamethasone sodium phosphate in vehicle) | EXPERIMENTAL | One drop twice daily (BID) in the study eye for 14 days. |
| SURF-200 (0.04% betamethasone sodium phosphate in vehicle) | EXPERIMENTAL | One drop BID in the study eye for 14 days. |
| Vehicle | PLACEBO_COMPARATOR | One drop BID in the study eye for 14 days. |
| Name | Type | Description |
|---|---|---|
| 0.02% Betamethasone Sodium Phosphate | DRUG | topical corticosteroid solution |
| 0.04% Betamethasone Sodium Phosphate | DRUG | topical corticosteroid solution |
| Placebo | DRUG | topical vehicle solution |
Inclusion Criteria: 1. Subjects 18 years of age and older who have a diagnosis of dry eye disease and experiencing an episodic flare up. Criteria for the diagnosis must include the following: 1. UNC DEMS score of greater than or equal to 5 but less than or equal to 9 2. Conjunctival hyperemi...
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-319 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
0.02% Betamethasone is being studied for the treatment of dry eye disease, specifically for patients experiencing an episodic flare-up of the condition. It is an investigational ophthalmic eye drop formulation. The research focuses on adults 18 years and older with dry eye disease in the United States.
0.02% Betamethasone is being developed by Harrow, Inc., which trades under the ticker symbol HROW. The company is advancing this ophthalmic small molecule formulation as a potential treatment for dry eye disease.
0.02% Betamethasone is in Phase 2 clinical development. The completed Phase 2 trial evaluated the eye drop in patients with dry eye disease. It is an investigational therapy and has not been approved by the FDA for any indication.
0.02% Betamethasone has been studied in one completed Phase 2 clinical trial, NCT04734210. The trial was a randomized, double-blind, placebo-controlled study that enrolled 139 participants with dry eye disease in the United States. It assessed the eye drop compared with vehicle in subjects experiencing an episodic flare-up.
Yes, 0.02% Betamethasone is also known as 0.02% Betamethasone Sodium Phosphate. The two names refer to the same ophthalmic formulation being developed by Harrow, Inc. for dry eye disease.